Logo image of KNE.CA

KANE BIOTECH INC (KNE.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:KNE - CA4838092084 - Common Stock

0.035 CAD
+0.01 (+16.67%)
Last: 12/18/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to KNE. KNE was compared to 22 industry peers in the Biotechnology industry. KNE has a bad profitability rating. Also its financial health evaluation is rather negative. KNE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KNE had negative earnings in the past year.
KNE had a negative operating cash flow in the past year.
KNE had negative earnings in 4 of the past 5 years.
In the past 5 years KNE always reported negative operating cash flow.
KNE.CA Yearly Net Income VS EBIT VS OCF VS FCFKNE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

1.2 Ratios

KNE's Return On Assets of -121.35% is in line compared to the rest of the industry. KNE outperforms 40.91% of its industry peers.
Industry RankSector Rank
ROA -121.35%
ROE N/A
ROIC N/A
ROA(3y)28.88%
ROA(5y)-12.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KNE.CA Yearly ROA, ROE, ROICKNE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K 40K 50K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KNE.CA Yearly Profit, Operating, Gross MarginsKNE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

KNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KNE has been increased compared to 1 year ago.
Compared to 5 years ago, KNE has more shares outstanding
Compared to 1 year ago, KNE has an improved debt to assets ratio.
KNE.CA Yearly Shares OutstandingKNE.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KNE.CA Yearly Total Debt VS Total AssetsKNE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -21.17, we must say that KNE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -21.17, KNE perfoms like the industry average, outperforming 40.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.17
ROIC/WACCN/A
WACC11.33%
KNE.CA Yearly LT Debt VS Equity VS FCFKNE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

2.3 Liquidity

KNE has a Current Ratio of 0.90. This is a bad value and indicates that KNE is not financially healthy enough and could expect problems in meeting its short term obligations.
KNE has a Current ratio (0.90) which is comparable to the rest of the industry.
KNE has a Quick Ratio of 0.90. This is a bad value and indicates that KNE is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.72, KNE is in line with its industry, outperforming 40.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.72
KNE.CA Yearly Current Assets VS Current LiabilitesKNE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for KNE have decreased strongly by -503.57% in the last year.
Looking at the last year, KNE shows a very negative growth in Revenue. The Revenue has decreased by -72.68% in the last year.
The Revenue has been growing slightly by 4.21% on average over the past years.
EPS 1Y (TTM)-503.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
Revenue 1Y (TTM)-72.68%
Revenue growth 3Y8.98%
Revenue growth 5Y4.21%
Sales Q2Q%-99.34%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNE.CA Yearly Revenue VS EstimatesKNE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KNE.CA Price Earnings VS Forward Price EarningsKNE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNE.CA Per share dataKNE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KNE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

KANE BIOTECH INC

TSX-V:KNE (12/18/2025, 7:00:00 PM)

0.035

+0.01 (+16.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-28 2025-11-28
Earnings (Next)04-27 2026-04-27
Inst Owners0.6%
Inst Owner ChangeN/A
Ins Owners39.39%
Ins Owner ChangeN/A
Market Cap5.86M
Revenue(TTM)574.90K
Net Income(TTM)-3.33M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.19
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -121.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)28.88%
ROA(5y)-12.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.7%
Cap/Sales 22.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.72
Altman-Z -21.17
F-Score2
WACC11.33%
ROIC/WACCN/A
Cap/Depr(3y)31.77%
Cap/Depr(5y)88.96%
Cap/Sales(3y)13.66%
Cap/Sales(5y)14.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-503.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-72.68%
Revenue growth 3Y8.98%
Revenue growth 5Y4.21%
Sales Q2Q%-99.34%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y52.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.2%
OCF growth 3YN/A
OCF growth 5YN/A

KANE BIOTECH INC / KNE.CA FAQ

What is the fundamental rating for KNE stock?

ChartMill assigns a fundamental rating of 1 / 10 to KNE.CA.


What is the valuation status for KNE stock?

ChartMill assigns a valuation rating of 0 / 10 to KANE BIOTECH INC (KNE.CA). This can be considered as Overvalued.


Can you provide the profitability details for KANE BIOTECH INC?

KANE BIOTECH INC (KNE.CA) has a profitability rating of 0 / 10.


Can you provide the financial health for KNE stock?

The financial health rating of KANE BIOTECH INC (KNE.CA) is 1 / 10.